Advances in the antiviral therapy of herpes virus infection in children

References

• Chalumeau M, Treluyer JM, Salanave B et al. Off label and unlicensed drug use among French office based paediatricians. Arch. Dis. Child. 83, 502–505 (2000).
   PubMed Web of Science ®Google Scholar
• Conroy S, Choonara I, Impicciatore P et al. Survey of unlicensed and off label drug use in paediatric wards in European countries. European Network for Drug Investigation in Children. Br. Med. J. 320, 79–82 (2000).
   PubMed Web of Science ®Google Scholar
• Eksborg S. The pharmacokinetics of antiviral therapy in paediatric patients. Herpes 10, 66–71 (2003).
   PubMedGoogle Scholar
• Paediatric Formulary Committee. BNF for Children. BMJ Publishing Group, RPS Publishing and RCPCH Publications, London, UK (2006).
   Google Scholar
• Fletcher C, Bean B. Evaluation of oral aciclovir therapy. Drug Intell. Clin. Pharm. 19, 518–524 (1985).
   PubMedGoogle Scholar
• MacDougall C, Guglielmo J. Pharmacokinetics of valaciclovir. J. Antimicrob. Chem. 53, 899–901 (2004).
   PubMed Web of Science ®Google Scholar
• Kimberlin D. Antiviral therapies in children: has their time arrived? Pediatr. Clin. North Am. 52, 837–867 (2005).
   PubMed Web of Science ®Google Scholar
• Bacon TH, Levin MJ, Leary JJ, Sarisky RT, Sutton D. Herpes simplex virus resistance to acyclovir and penciclovir after two decades of antiviral therapy. Clin. Microbiol. Rev. 16, 114–128 (2003).
   PubMed Web of Science ®Google Scholar
• Coen D. Acyclovir-resistant pathogenic herpes viruses. Trends Microbiol. 2, 481–485 (1994).
   PubMedGoogle Scholar
• Danve-Szatanek C, Aymard M, Thouvenot D et al. Surveillance network for herpes simplex virus resistance to antiviral drugs: 3-year follow-up. J. Clin. Microbiol.42, 242–249 (2004).
   PubMed Web of Science ®Google Scholar
• Tyring SK, Baker D, Snowden W. Valacyclovir for herpes simplex virus infection: long-term safety and sustained efficacy after 20 years’ experience with acyclovir. J. Infect. Dis. 186(Suppl. 1), S40–S46 (2002).
   PubMed Web of Science ®Google Scholar
• Eksborg S, Pal N, Kalin M, Palm C, Soderhall S. Pharmacokinetics of acyclovir in immunocompromized children with leukopenia and mucositis after chemotherapy: can intravenous acyclovir be substituted by oral valacyclovir? Med. Pediatr. Oncol. 38, 240–246 (2002).
   PubMedGoogle Scholar
• Sullender W, Arvin A, Diaz P et al. Pharmacokinetics of acyclovir suspension in infants and children. Antimicrob. Agents Chemother. 31, 1722–1726 (1987).
   PubMed Web of Science ®Google Scholar
• Pacifici GM. Pharmacokinetics of antivirals in neonate. Early Hum. Dev. 81, 773–780 (2005).
   PubMed Web of Science ®Google Scholar
• Steingrimsdottir H, Gruber A, Palm C et al. Bioavailability of aciclovir after oral administration of aciclovir and its prodrug valaciclovir to patients with leukopenia after chemotherapy. Antimicrob. Agents Chemother. 44, 207–209 (2000).
   PubMed Web of Science ®Google Scholar
• Englund J, Fletcher C, Balfour H. Acyclovir therapy in neonates. J. Pediatr. 119, 129–135 (1991).
   PubMed Web of Science ®Google Scholar
• Kimberlin DW, Lin CY, Jacobs RF et al. Safety and efficacy of high-dose intravenous acyclovir in the management of neonatal herpes simplex virus infections. Pediatrics 108, 230–238 (2001).
   PubMed Web of Science ®Google Scholar
• Nadal D, Leverger G, Sokal ME et al. An investigation of the steady-state pharmacokinetics of oral valacyclovir in immunocompromised children. J. Infect. Dis. 186, S123–S130 (2002).
   PubMedGoogle Scholar
• Chakrabarty A, Tyring SK, Beutner K, Rauser M. Recent clinical experience with famciclovir – a ‘third generation’ nucleoside prodrug. Antivir. Chem. Chemother. 15, 251–253 (2004).
   PubMedGoogle Scholar
• Fan-Havard P, Nahata MC, Brady MT. Ganciclovir – a review of pharmacology, therapeutic efficacy and potential use for treatment of congenital cytomegalovirus infections. J. Clin. Pharm. Ther. 14, 329–340 (1989).
   PubMedGoogle Scholar
• Frenkel L, Capparelli E, Dankner WM et al. Oral ganciclovir in children: pharmacokinetics, safety, tolerance, and antiviral effects. J. Infect. Dis. 182, 1616–1624 (2000).
   PubMed Web of Science ®Google Scholar
• Kimberlin D, Lin C, Sanchez P et al. Effect of ganciclovir therapy on hearing in symptomatic congenital cytomegalovirus disease involving the central nervous system: a randomized, controlled trial. J. Pediatr. 143, 16–25 (2003).
   PubMed Web of Science ®Google Scholar
• Whitley RJ, Cloud G, Gruber W et al. Ganciclovir treatment of symptomatic congenital cytomegalovirus infection: results of a Phase II study. National Institute of Allergy and Infectious Diseases Collaborative Antiviral Study Group. J. Infect. Dis. 175, 1080–1086 (1997).
   PubMed Web of Science ®Google Scholar
• Ernst ME, Franey RJ. Acyclovir- and ganciclovir-induced neurotoxicity. Ann. Pharmacother. 32, 111–113 (1998).
   PubMed Web of Science ®Google Scholar
• Emery VC and Griffiths PD. Prediction of cytomegalovirus load and resistance patterns after antiviral chemotherapy. Proc. Natl Acad. Sci. USA 97, 8039–8044 (2000).
   PubMed Web of Science ®Google Scholar
• Trang JM, Kidd L, Gruber W et al. Linear single-dose pharmacokinetics of ganciclovir in newborns with congenital cytomegalovirus infections. NIAID Collaborative Antiviral Study Group. Clin. Pharmacol. Ther. 53, 15–21 (1993).
   PubMed Web of Science ®Google Scholar
• Zhou XJ, Gruber W, Demmler G et al. Population pharmacokinetics of ganciclovir in newborns with congenital cytomegalovirus infections. NIAID Collaborative Antiviral Study Group. Antimicrob. Agents Chemother. 40, 2202–2205 (1996).
   PubMed Web of Science ®Google Scholar
• Sugawara M, Huang W, Fei YJ et al. Transport of valganciclovir, a ganciclovir prodrug, via peptide transporters PEPT1 and PEPT2. J. Pharm. Sci. 89, 781–789 (2000).
   PubMed Web of Science ®Google Scholar
• Razonable R, Paya CV. Valganciclovir for the prevention and treatment of cytomegalovirus disease in immunocompromised hosts. Expert Rev. Anti Infect. Ther. 2, 27–42 (2004).
   PubMedGoogle Scholar
• Jain A, Orloff M, Kashyap R et al. Does valganciclovir hydrochloride (valcyte) provide effective prophylaxis against cytomegalovirus infection in liver transplant recipients? Transplant. Proc. 37, 3182–3186 (2005).
   PubMedGoogle Scholar
• Clark BS, Chang IF, Karpen SJ et al. Valganciclovir for the prophylaxis of cytomegalovirus disease in pediatric liver transplant recipients. Transplantation 77, 1480 (2004).
   PubMed Web of Science ®Google Scholar
• Paya C, Humar A, Dominguez E et al. Efficacy and safety of valganciclovir vs oral ganciclovir for prevention of cytomegalovirus disease in solid organ transplant recipients. Am. J. Transplant. 4, 611–620 (2004).
   PubMed Web of Science ®Google Scholar
• Martin DF, Sierra-Madero J, Walmsley S et al. A controlled trial of valganciclovir as induction therapy for cytomegalovirus retinitis. N. Engl. J. Med. 346, 1119–1126 (2002).
   PubMed Web of Science ®Google Scholar
• Peyriere H, Jeziorsky E, Jalabert A et al. Neurotoxicity related to valganciclovir in a child with impaired renal function: usefulness of therapeutic drug monitoring. Ann. Pharmacother. 40, 143–146 (2006).
   PubMed Web of Science ®Google Scholar
• Anaizi NH, Dentinger PJ, Swenson CF. Stability of valganciclovir in an extemporaneously compounded oral liquid. Am. J. Health Syst. Pharm. 59, 1267–1270 (2002).
   PubMedGoogle Scholar
• Henkin CC, Griener JC, Ten Eick AP. Stability of valganciclovir in extemporaneously compounded liquid formulations. Am. J. Health Syst. Pharm. 60, 687–690 (2003).
   PubMedGoogle Scholar
• Burri M, Wiltshire H, Kahlert C, Wouters G, Rudin C. Oral valganciclovir in children: single dose pharmacokinetics in a six-year-old girl. Pediatr. Infect. Dis. J. 23, 263–266 (2004).
   PubMed Web of Science ®Google Scholar
• Meine Jansen CF, Toet MC, Rademaker CM et al. Treatment of symptomatic congenital cytomegalovirus infection with valganciclovir. J. Perinat. Med. 33, 364–366 (2005).
   PubMed Web of Science ®Google Scholar
• DeClercq E and Holy A. Acyclic nucleoside phosphonates: a key class of antiviral drugs. Nat. Rev. Drug Discov. 4, 928–940 (2005).
   PubMedGoogle Scholar
• Biron KK. Antiviral drugs for cytomegalovirus diseases. Antiviral Res. 71, 154–163 (2006).
   PubMed Web of Science ®Google Scholar
• Lynn R, Knowles R, Preece M, Smith A. Royal College of Paediatrics and Child Health British Paediatric Surveillance Unit 18th Annual Report, 2003–2004. (2004).
   Google Scholar
• Maschmann J, Hamprecht K, Dietz K, Jahn G, Speer CP. Cytomegalovirus infection of extremely low-birth weight infants via breast milk. Clin. Infect. Dis. 33, 1998–2003 (2001).
   PubMed Web of Science ®Google Scholar
• Cheong JLY, Cowan FM, Modi N. Gastrointestinal manifestations of postnatal cytomegalovirus infection in infants admitted to a neonatal intensive care unit over a five year period. Arch. Dis. Child. Fetal Neonatal Ed. 89, F367–F369 (2004).
   PubMed Web of Science ®Google Scholar
• Rongkavilit C, Bedard MP, Ang JY, Asmar BI, Tolia V. Severe cytomegalovirus enterocolitis in an immunocompetent infant. Pediatr. Infect. Dis. J. 23, 579–581 (2004).
   PubMed Web of Science ®Google Scholar
• Rubin R. The indirect effects of cytomegalovirus infection on the outcome of organ transplantation. JAMA 261, 3607–3609 (1989).
   PubMed Web of Science ®Google Scholar
• Gane E, Saliba F, Valdecasas GJ et al. Randomised trial of efficacy and safety of oral ganciclovir in the prevention of cytomegalovirus disease in liver-transplant recipients. Lancet 350, 1729–1733 (1997).
   PubMed Web of Science ®Google Scholar
• Goodrich JM, Bowden RA, Fisher L et al. Ganciclovir prophylaxis to prevent cytomegalovirus disease after allogeneic marrow transplant. Ann. Intern. Med. 118, 173–178 (1993).
   PubMed Web of Science ®Google Scholar
• Hodson EM, Barclay PG, Craig JC et al. Antiviral medications for preventing cytomegalovirus disease in solid organ transplant recipients. Cochrane Database Syst. Rev. 4, CD003774 (2005).
   Google Scholar
• Singh N. Antiviral drugs for cytomegalovirus in transplant recipients: advantages of preemptive therapy. Rev. Med. Virol.16(5), 281–287 (2006).
   PubMed Web of Science ®Google Scholar
• Strippoli GF, Hodson EM, Jones CJ, Craig JC. Pre-emptive treatment for cytomegalovirus viraemia to prevent cytomegalovirus disease in solid organ transplant recipients. Transplantation 81, 139–145 (2006).
   PubMed Web of Science ®Google Scholar
• Annemans L, Moeremans K, Mutimer D et al. Modeling costs and cost-effectiveness of different CMV management strategies in liver transplant recipients as a support for current and future decision making. Value Health 5, 347–358 (2002).
   PubMedGoogle Scholar
• Snydman R. The case for cytomegalovirus prophylaxis in solid organ transplantation. Rev. Med. Virol. 16(5), 289–295(2006).
   PubMed Web of Science ®Google Scholar
• Cesaro S, Zhou X, Manzardo C et al. Cidofovir for cytomegalovirus reactivation in pediatric patients after hematopoietic stem cell transplantation. J. Clin. Virol. 34, 129–132 (2005).
   PubMedGoogle Scholar
• Hewlett G, Hallenberger S, Rubsamen-Waigmann H. Antivirals against DNA viruses (hepatitis B and the herpes viruses). Curr. Opin. Pharmacol. 4, 453–464 (2004).
   PubMedGoogle Scholar
• Lalezari J, Aberg J, Wang L et al. Phase I dose escalation trial evaluating the pharmacokinetics, anti-human cytomegalovirus (HCMV) activity, and safety of 1263W94 in human immunodeficiency virus-infected men with asymptomatic HCMV shedding. Antimicrob. Agents Chemother. 46, 2969–2976 (2002).
   PubMed Web of Science ®Google Scholar
• Roberts CM, Pfister JR, Spear SJ. Increasing proportion of herpes simplex virus type 1 as a cause of genital herpes infection in college students. Sex. Transm. Dis. 30, 797–800 (2003).
   PubMed Web of Science ®Google Scholar
• Khan B, Pavan-Langston D. Clinical manifestations and treatment modalities in herpes simplex virus of the ocular anterior segment. Int. Ophthalmol. Clin. 44, 103–133 (2004).
   PubMedGoogle Scholar
• Nikkels A, Pierard G. Treatment of mucocutaneous presentations of herpes simplex virus infections. Am. J. Clin. Dermatol. 3, 475–487 (2002).
   PubMedGoogle Scholar
• Amir J, Harel L, Smetana Z, Varsano I. Treatment of herpes simplex gingivostomatitis with aciclovir in children: a randomised double blind placebo controlled study. Br. Med. J. 314, 1800 (1997).
   PubMedGoogle Scholar
• Spruance SL, Nett R, Marbury T et al. Acyclovir cream for treatment of herpes simplex labialis: results of two randomized, double-blind, vehicle-controlled, multicenter clinical trials. Antimicrob. Agents Chemother. 46, 2238–2243 (2002).
   PubMed Web of Science ®Google Scholar
• McKeough MB, Spruance SL. Comparison of new topical treatments for herpes labialis: efficacy of penciclovir cream, acyclovir cream, and n-docosanol cream against experimental cutaneous herpes simplex virus type 1 infection. Arch. Dermatol. 137, 1153–1158 (2001).
   PubMedGoogle Scholar
• Spruance SL, Stewart JC, Rowe NH et al. Treatment of recurrent herpes simplex labialis with oral acyclovir. J. Infect. Dis. 161, 185–190 (1990).
   PubMed Web of Science ®Google Scholar
• Wilhelmus KR, Beck RW, Moke PS et al. Acyclovir for the prevention of recurrent herpes simplex virus eye disease. N. Engl. J. Med. 339, 300–306 (1998).
   PubMed Web of Science ®Google Scholar
• Vander Straten M, Carrasco D, Lee P, Tyring SK. A review of antiviral therapy for herpes labialis. Arch. Dermatol. 137, 1232–1235 (2001).
   PubMedGoogle Scholar
• Spruance SL, Jones TM, Blatter MM et al. High-dose, short-duration, early valacyclovir therapy for episodic treatment of cold sores: results of two randomized, placebo-controlled, multicenter studies. Antimicrob. Agents Chemother. 47, 1072–1080 (2003).
   PubMed Web of Science ®Google Scholar
• Whitley RJ, Kimberlin DW. Herpes simplex encephalitis: children and adolescents. Semin. Pediatr. Infect. Dis. 16, 17–23 (2005).
   PubMedGoogle Scholar
• De Tiege X, Rozenberg F, Des Portes V et al. Herpes simplex encephalitis relapses in children: differentiation of two neurologic entities. Neurology 61, 241–243 (2003).
   PubMed Web of Science ®Google Scholar
• Handsfield HH, Waldo AB, Brown ZA et al. Neonatal herpes should be a reportable disease. Sex. Transm. Dis. 32, 521–525 (2005).
   PubMed Web of Science ®Google Scholar
• Ambinder R, Burns W, Lietman P, Saral R. Prophylaxis: a strategy to minimise antiviral resistance. Lancet 1, 1154–1155 (1984).
   PubMed Web of Science ®Google Scholar
• Chen Y, Scieux C, Garrait V et al. Resistant herpes simplex virus type 1 infection: an emerging concern after allogeneic stem cell transplantation. Clin. Infect. Dis. 31, 927–935 (2000).
   PubMed Web of Science ®Google Scholar
• Kleymann G, Fischer R, Betz UA et al. New helicase-primase inhibitors as drug candidates for the treatment of herpes simplex disease. Nat. Med. 8, 392–398 (2002).
   PubMed Web of Science ®Google Scholar
• Crute JJ, Grygon CA, Hargrave KD et al. Herpes simplex virus helicase-primase inhibitors are active in animal models of human disease. Nat. Med. 8, 386–391 (2002).
   PubMed Web of Science ®Google Scholar
• Kleymann G. Agents and strategies in development for improved management of herpes simplex virus infection and disease. Expert Opin. Investig. Drugs 14, 135–161 (2005).
   PubMed Web of Science ®Google Scholar
• Brisson M, Edmunds WJ. Epidemiology of varicella-zoster virus in England and Wales. J. Med. Virol. 70(Suppl. 1), S9–S14 (2003).
   PubMedGoogle Scholar
• Miller E, Marshall R, Vurdien J. Epidemiology, outcome and control of varicella-zoster infection. Rev. Med. Microbiol. 4, 222–230 (1993).
   Google Scholar
• Enright AM, Prober C. Antiviral therapy in children with VZV and HSV infections. Herpes 10, 32–37 (2003).
   PubMedGoogle Scholar
• Klassen TP, Hartling L, Wiebe N, Belseck EM. Acyclovir for treating varicella in otherwise healthy children and adolescents. Cochrane Database Syst. Rev. 4 (2005).
   Google Scholar
• American Academy of Pediatrics. Varicella-zoster infections. In: Red Book: 2003 Report of the Committee on Infectious Diseases American Academy of Pediatrics (26th Edition). Pickering LK (Ed.). American Academy of Pediatrics, IL, USA, 711–725 (2003).
   Google Scholar
• Morgan-Capner P, Crowcroft N. Guidelines on the management of, and exposure to, rash illness in pregnancy (including consideration of relevant antibody screening programmes in pregnancy). Commun. Dis. Public Health 5, 59–71 (2002).
   PubMedGoogle Scholar
• Wassilew SW, Wutzler P. Oral brivudin in comparison with acyclovir for herpes zoster: a survey study on postherpetic neuralgia. Antiviral Res. 59, 57–60 (2003).
   PubMed Web of Science ®Google Scholar
• Wassilew S. Brivudin compared with famciclovir in the treatment of herpes zoster: effects in acute disease and chronic pain in immunocompetent patients. A randomized, double-blind, multinational study. J. Eur. Acad. Dermatol. Venereol.19, 47–55 (2005).
   PubMed Web of Science ®Google Scholar
• Clercq ED. Discovery and development of BVDU (brivudin) as a therapeutic for the treatment of herpes zoster. Biochem. Pharmacol. 68, 2301–2315 (2004).
   PubMedGoogle Scholar
• Koelle D. Vaccines for herpes simplex virus infections. Curr. Opin. Investig. Drugs 7, 136–141 (2006).
   PubMedGoogle Scholar
• Schleiss M. Progress in cytomegalovirus vaccine development. Herpes 12, 66–75 (2005).
   PubMedGoogle Scholar
• Nigro G, Scholz H, Bartmann U. Ganciclovir therapy for symptomatic congenital cytomegalovirus infection in infants: a two-regimen experience. J. Pediatr. 124, 318–322 (1994).
   PubMed Web of Science ®Google Scholar
• Halwachs-Baumann G, Genser B, Pailer S et al. Human cytomegalovirus load in various body fluids of congenitally infected newborns. J. Clin. Virol. 25(Suppl. 3), S81–S87 (2002).
   PubMedGoogle Scholar
• Michaels MG, Greenberg DP, Sabo DL, Wald ER. Treatment of children with congenital cytomegalovirus infection with ganciclovir. Pediatr. Infect. Dis. J. 22, 504–508 (2003).
   PubMed Web of Science ®Google Scholar
• Rojo P and Ramos JT. Ganciclovir treatment of children with congenital cytomegalovirus infection. Pediatr. Infect. Dis. J. 23, 88–89 (2004).
   PubMedGoogle Scholar
• Tanaka-Kitajima N, Sugaya N, Futatani T et al. Ganciclovir therapy for congenital cytomegalovirus infection in six infants. Pediatr. Infect. Dis. J. 24, 782–785 (2005).
   PubMed Web of Science ®Google Scholar